Scarica l'app Stockscreener
21.40
3.34%
-0.74
Dopo l'orario di chiusura:
21.50
0.10
+0.47%
Precedente Chiudi:
$22.14
Aprire:
$21.96
Volume 24 ore:
1.18M
Relative Volume:
0.85
Capitalizzazione di mercato:
$1.86B
Reddito:
$139.71M
Utile/perdita netta:
$-209.36M
Rapporto P/E:
-7.2297
EPS:
-2.96
Flusso di cassa netto:
$-160.60M
1 W Prestazione:
+4.24%
1M Prestazione:
+0.71%
6M Prestazione:
+32.67%
1 anno Prestazione:
+38.24%
Intervallo 1D:
$21.00
$22.39
Intervallo di 1 settimana:
$19.21
$22.68
Portata 52W:
$8.58
$22.73
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Nome
Syndax Pharmaceuticals Inc
Settore
Industria
Telefono
781-419-1400
Indirizzo
730 THIRD AVENUE, NEW YORK, MA
Compare SNDX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
21.40 | 1.92B | 139.71M | -209.36M | -160.60M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.27 | 123.47B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
766.66 | 83.60B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
748.72 | 46.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.65 | 43.11B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
297.04 | 34.79B | 4.98B | 69.60M | 525.67M | 0.5198 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-16 | Ripresa | H.C. Wainwright | Buy |
| 2025-09-10 | Ripresa | Stifel | Buy |
| 2025-09-04 | Ripresa | Guggenheim | Buy |
| 2025-08-05 | Reiterato | BTIG Research | Buy |
| 2025-07-10 | Iniziato | Goldman | Buy |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-06-28 | Iniziato | Jefferies | Buy |
| 2024-01-31 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| 2023-12-22 | Iniziato | Mizuho | Buy |
| 2023-10-25 | Iniziato | BofA Securities | Buy |
| 2023-10-11 | Iniziato | Goldman | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Outperform |
| 2023-07-11 | Iniziato | Guggenheim | Buy |
| 2023-04-17 | Ripresa | BTIG Research | Buy |
| 2023-01-31 | Iniziato | Stifel | Buy |
| 2023-01-03 | Iniziato | JP Morgan | Overweight |
| 2022-07-28 | Ripresa | B. Riley Securities | Buy |
| 2022-04-11 | Iniziato | H.C. Wainwright | Buy |
| 2022-02-15 | Iniziato | Goldman | Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-05-25 | Iniziato | Citigroup | Buy |
| 2021-02-18 | Iniziato | B. Riley Securities | Buy |
| 2020-12-03 | Iniziato | Stifel | Buy |
| 2020-05-22 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-05-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-05-18 | Downgrade | Citigroup | Buy → Neutral |
| 2020-05-11 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-13 | Reiterato | H.C. Wainwright | Buy |
| 2019-03-08 | Reiterato | H.C. Wainwright | Buy |
| 2019-01-04 | Iniziato | Robert W. Baird | Outperform |
| 2018-01-05 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-03-16 | Iniziato | FBR & Co. | Outperform |
| 2017-03-02 | Iniziato | Instinet | Buy |
| 2016-10-07 | Iniziato | Guggenheim | Buy |
| 2016-03-28 | Iniziato | Citigroup | Buy |
| 2016-03-28 | Iniziato | JMP Securities | Mkt Outperform |
| 2016-03-28 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Syndax Pharmaceuticals Inc Borsa (SNDX) Ultime notizie
Is Syndax Pharmaceuticals (SNDX) Pricing Reflect Pipeline Progress Or Stretching Recent Share Gains - simplywall.st
SNDX Receives Buy Rating as Citigroup Raises Price Target to $57 - GuruFocus
Syndax Pharmaceuticals (NASDAQ:SNDX) Given New $57.00 Price Target at Citigroup - MarketBeat
Syndax Pharmaceuticals Inc. (SNDX) on a Strong Footing amid Robust Demand for Key Flagship Drugs - Bitget
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2025 Earnings Call Transcript - Insider Monkey
Barclays Sticks to Their Buy Rating for Syndax Pharmaceuticals (SNDX) - The Globe and Mail
11 Best Cancer Stocks to Invest In Now - Insider Monkey
Syndax Pharmaceuticals (NASDAQ:SNDX) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Is Syndax (SNDX) Using ESOP Shares and New Drugs to Quietly Redefine Its Investment Story? - Yahoo Finance
Syndax (SNDX) Q4 2025 Earnings Call Transcript - Intellectia AI
SNDX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Syndax Pharmaceuticals Q4 Earnings Call Highlights - Yahoo Finance
Discipline and Rules-Based Execution in SNDX Response - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX) and Syndax Pharmaceuticals (SNDX) - The Globe and Mail
Decoding Syndax Pharmaceuticals Inc (SNDX): A Strategic SWOT Ins - GuruFocus
Syndax Pharmaceuticals (SNDX) Reports Strong 2025 Earnings and Growth Prospects - GuruFocus
Syndax Pharmaceuticals (NASDAQ:SNDX) Announces Quarterly Earnings Results, Misses Expectations By $0.12 EPS - MarketBeat
Syndax Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Syndax Pharmaceuticals (SNDX) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Syndax (SNDX) Projects Stable Operating Expenses and Path to Pro - GuruFocus
Syndax (SNDX) Exceeds Revenue Expectations, Anticipates Continued Growth - GuruFocus
Syndax Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Q4 2025 Syndax Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Earnings Flash (SNDX) Syndax Pharmaceuticals, Inc. Reports Q4 Revenue $68.7M, vs. FactSet Est of $64.3M - marketscreener.com
BRIEF-Syndax Pharmaceuticals Q4 Operating Expenses USD 131.276 Million - TradingView
Cancer drug maker Syndax posts $172M sales, eyes profitability - Stock Titan
Syndax faces earnings test as cancer drug launches accelerate By Investing.com - Investing.com UK
Syndax faces earnings test as cancer drug launches accelerate - Investing.com India
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Syndax Pharmaceuticals, Inc. announces that patient enrollment has been completed for its Phase II clinical trial of Axatilimab for idiopathic pulmonary fibrosis (IPF). - Bitget
VIX Spike: Is Syndax Pharmaceuticals Inc stock showing strong momentumBull Run & High Yield Equity Trading Tips - baoquankhu1.vn
Biotech CEO plans three March investor Q&As in Boston and Miami - Stock Titan
Syndax Pharmaceuticals (SNDX) Projected to Post Earnings on Monday - Defense World
Aberdeen Group plc Grows Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Is Syndax Pharmaceuticals Inc. a speculative investment2025 Price Momentum & Accurate Trade Setup Notifications - mfd.ru
Earnings Miss: Does Syndax Pharmaceuticals Inc. have strong fundamentalsQuarterly Investment Review & Safe Capital Investment Plans - mfd.ru
Can Syndax Pharmaceuticals Inc. stock double in the next yearInsider Selling & Precise Trade Entry Recommendations - mfd.ru
Syndax Pharmaceuticals (SNDX) Stock Analysis: An 88% Potential Upside Ignites Investor Interest - DirectorsTalk Interviews
Syndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call ... - Bluefield Daily Telegraph
Syndax to Announce Fourth Quarter and Full Year 2025 - GlobeNewswire
Cancer drug maker Syndax to review 2025 results in Feb. 26 earnings call - Stock Titan
Syndax Pharmaceuticals Highlights Revuforj, Niktimvo Sales Surge and 2026 Milestones at Guggenheim Conf - Defense World
Why Analysts See Syndax Pharmaceuticals (SNDX) Story Evolving With New Deals And Refined Valuation - Yahoo Finance
Behavioral Patterns of SNDX and Institutional Flows - Stock Traders Daily
How Revuforj’s Global Access Push At Syndax Pharmaceuticals (SNDX) Has Changed Its Investment Story - Sahm
Is Syndax Pharmaceuticals (SNDX) Pricing Reflecting Recent Biotech Reassessment Or Long Term Potential - Yahoo Finance
Does Syndax Pharmaceuticals Inc. meet Warren Buffett’s criteriaShare Buyback & Consistent Profit Alerts - mfd.ru
BofA Raised Syndax (SNDX) PT to $28, Cites Heavy Pre-Announcements Lowering Earnings Impact - Bitget
A Look At Syndax Pharmaceuticals (SNDX) Valuation After Revuforj Data And New Managed Access Program - Sahm
11 Most Promising Low-Cost Stocks to Buy Now - Insider Monkey
Have Insiders Sold Syndax Pharmaceuticals Shares Recently? - simplywall.st
Syndax Pharmaceuticals Inc Azioni (SNDX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
5.71%
0.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):